Prospective Evaluation of FibroScan for the Diagnosis of Hepatic Fibrosis Compared with Liver Biopsy/AST Platelet Ratio Index and FIB-4 in Patients with Chronic HBV Infection
- 681 Downloads
The FibroScan (FS), the aspartate aminotransferase-to-platelet ratio index (APRI), and the FIB-4 index are simple and inexpensive methods to detect liver fibrosis.
The primary objective was to evaluate the performance of FS for the noninvasive diagnosis of hepatic fibrosis in Western Chinese patients with chronic hepatitis B virus (HBV) infection compared with APRI and FIB-4; the secondary objective was to determine liver stiffness measurement (LSM) cutoff values for the noninvasive diagnosis of significant fibrosis and liver cirrhosis.
Overall, 175 consecutive patients with chronic HBV infection, successful liver biopsy, and alanine aminotransferase levels ≤2× ULN were prospectively studied. Liver fibrosis was graded by an independent pathologist using the METAVIR (F0–F4) classification. APRI and FIB-4 were calculated from laboratory data.
The area under receiver operating characteristics curves (AUROC) for LSM for significant fibrosis (METAVIR F2–3) and cirrhosis (F4) was 0.95 (95% confidence interval, 0.91–0.98) and 0.98 (0.96–0.99), respectively. For the detection of significant fibrosis and cirrhosis, the AUROC of APRI were 0.81 (0.74–0.87) and 0.83 (0.77–0.90); the AUROC of FIB-4 were 0.86 (0.80–0.91) and 0.77 (0.68–0.85). FS optimal cutoff values for the identification of significant fibrosis and cirrhosis were 7.9 and 13.8 kPa, respectively.
FS is a reliable predictor of significant fibrosis and cirrhosis in Western Chinese patients with chronic HBV infection, and is superior to APRI and FIB-4. FS cutoff values could be considered as clinical reference for detecting significant fibrosis and cirrhosis.
KeywordsAPRI Chronic HBV infection FIB-4 FibroScan Liver biopsy
We wish to thank all patients who participated in the study. We also thank Prof. Li-Chun Wang and Bing-Jun Lei (Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China) who agreed to have their patients participate in this study. This work was financially supported by the National Key Technologies Research and Development Program of China during the 11th Five-Year Plan Period (No.2008ZX10002-006), National S&T Major Project for Infections Diseases Control (No.2009ZX10004-905), and the National Basic Research Program of China (No.2007CB512902).
- 13.Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases CMA. Guideline on prevention and treatment of chronic hepatitis B in China (2005). Chin Med J (Engl). 2007;120:2159–2173.Google Scholar
- 21.Fung JLC, Cheng C, Wu CH, Wong D, Yuen MF. Mild-to-moderate elevation of alanine aminotransferase may increase liver stiffness measurement by transient elastography in patients with chronic hepatitis B. Hepatol. 2009;50:971A.Google Scholar
- 22.Fung JLC, But D, Hsu A, Seto WK, Cheng C, Wong DKH, Yuen MF. Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. Hepatol Int. 2010;4:716–722.Google Scholar
- 32.Gonzalez Guilabert MI, Hinojosa Mena-Bernal C, del Pozo Gonzalez J, del Pozo Perez MA. Retrospective study of FibroScan, APRI, FIB-4 and FORNS indexes compared with liver biopsy in the evaluation of liver fibrosis in patients with chronic hepatitis C monoinfection and HIV coinfection. Gastroenterol Hepatol. 2010;33:425–432.PubMedCrossRefGoogle Scholar